Comments
Drug firm Unichem Laboratories on Friday said it has received approval from the US health regulator to market Apremilast tablets, used for treatment of plaque psoriasis.
Apremilast tablets are indicated for the treatment of adult patients with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy.
Also read: Sun Pharma gains 2% on launching psoriasis drug in Japan
The company has received abbreviated new drug application (ANDA) approval to market its Apremilast tablets in the strengths of 10 mg, 20 mg and 30 mg from the United States Food and Drug Administration (USFDA), Unichem Labs said in a regulatory filing.
The approved product is a generic version of Amgen's Otezla tablets.
Shares of Unichem Labs were trading 1.36 per cent higher at ₹309.75 apiece on the BSE.
Comments
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.